Deepwise Medical Secures RMB 500 Million Funding to Pioneer China's Billion-Dollar AI Healthcare Market

On January 24, 2025, DeepWise announced the completion of a new round of financing totaling nearly RMB 500 million, aiming to deepen the application of artificial intelligence technologies in healthcare scenarios and build a comprehensive, end-to-end AI-driven digital intelligence ecosystem. This represents one of the largest financing rounds in the AI sector in recent years.

As one of China’s first digital-intelligence healthcare enterprises, DeepWise’s eight-year development has witnessed every major milestone in the country’s medical AI industry. Amidst the surging tides of the medical AI sector, DeepWise has remained steadfast.

Amid the current capital winter, DeepWise’s securing of another substantial round of financing underscores the industry’s and investors’ recognition of its outstanding performance in the medical AI sector. We look forward to DeepWise maintaining its leadership, achieving breakthroughs, and successfully driving the large-scale industrialization of medical AI applications.

Similar to most medical AI companies, DeepWise initially focused on imaging AI as its core competency, enhancing the efficiency and accuracy of physicians’ diagnoses. In doing so, it not only effectively expanded the supply of medical resources but also promoted the digital and intelligent transformation of China’s healthcare system.

There are no shortcuts in the R&D of AI for medical imaging. To stand out in this sector, companies must gain deep insights into genuine clinical needs, develop single-point AI applications as quickly and efficiently as possible, and achieve coverage across a broad range of disease types. As clinical adoption deepens, it becomes essential to effectively integrate these standalone AI applications into efficient solutions that align closely with clinical workflows, thereby laying a solid foundation for subsequent commercialization.

Across the entire AI medical imaging landscape, DeepWise stands unparalleled in its R&D capabilities and understanding of market needs. As of 2025, DeepWise leads the industry with 14 Class III medical device registrations approved by the National Medical Products Administration (NMPA), recording nearly 200 million AI invocations annually. Its intelligent solutions empower commonly used hospital equipment, including DR, CT, and mammography systems. The company provides AI-assisted diagnostics for high-volume daily screenings of systemic conditions such as thoracic, cardiovascular and cerebrovascular diseases, women’s health issues, and pediatric growth and development, establishing itself as a representative force of new quality productive forces.

However, the era of digital-intelligent healthcare is not driven solely by imaging data. Healthcare systems contain vast amounts of multi-modal data. To make diagnostic decisions akin to those of real physicians, AI companies must develop comprehensive models capable of processing cross-modal data, thereby maximizing the value embedded in medical data.

Therefore, after completing the initial construction of its imaging AI ecosystem, DeepWise acquired Yitu Healthcare in 2021 to bolster its intelligent data processing capabilities for medical big data. This strategic move established a dual-AI engine integrating “imaging + text,” expanding application scenarios from AI-assisted diagnosis of multi-organ and multi-system diseases to standardized and systematic research on medical big data. By significantly empowering education and scientific research, this initiative has ushered in deeper, more intelligent, and precise AI-driven research in the healthcare sector.

Medicine is a complex and rigorous discipline. Physicians’ diagnosis of diseases relies not only on the interpretation of medical images but, more importantly, on comprehensive analysis of multimodal data—including imaging, laboratory tests, pathology, and genomics—based on their rich internal knowledge graphs of medicine, ultimately leading to clinical decision-making. In September 2024, DeepWise obtained its 14th Class III certification from the National Medical Products Administration (NMPA), marking the first Class III certification for an AI-based lung cancer diagnostic product in China. This product integrates imaging data with clinicians’ expertise, leveraging model training on tens of thousands of cases with pathological gold-standard data and at least two years of follow-up data. It provides differentiation between benign and malignant small pulmonary nodules, offering physicians highly specific auxiliary diagnostic results for nodule characterization. The approval of this Class III certification represents a milestone breakthrough in the field of medical artificial intelligence. With this achievement, AI products have transcended the limitations of mere detection and triage, beginning to provide physicians with true diagnostic assistance.

We observe that DeepWise appears to be carving out a unique development path in the field of medical AI. Technologically, it is advancing from single-image segmentation to lesion detection and disease diagnosis; in product development, it is evolving from standalone products to multi-product portfolios and comprehensive solutions; and in terms of coverage, it is progressing from single-modality imaging data to complex multimodal data.

This signifies that DeepWise has evolved from a pure-play imaging AI company into a comprehensive medical AI enterprise, capable of deeply unlocking the value of multimodal data within healthcare systems and thereby building a digital ecosystem that serves the entire medical process across all scenarios.

With the continuous iteration of medical AI, a large number of hospitals and physicians have fully recognized the value of various AI applications, regarding them as essential tools for daily practice. Leveraging its dual AI engines for “imaging + text,” DeepWise has built the Deepwise MetAI intelligent imaging and big data general-purpose platform, as well as the Deepwise TrioData multimodal medical big data platform, currently providing artificial intelligence services to thousands of institutions.

Unlike most medical imaging AI products, Deepwise MetAI goes beyond the AI-based detection and diagnosis of single imaging findings. By aligning with physicians’ diagnostic logic and workflow, it builds an intelligent department featuring “end-to-end, all-scenario AI-driven digital intelligence.” Deepwise TrioData places greater emphasis on the integration and governance of hospital-wide multimodal big data, helping hospitals manage high-quality data assets and delivering intelligent products and services across multiple scenarios, including management, scientific research, clinical practice, and AI capability development.

The field of health checkups is also an emerging application scenario for AI imaging in China. Under the strategic goal of “Health for All,” DeepWise has proactively positioned itself in this sector. Its Smart Health team provides personalized, professional, and intelligent services to major health checkup institutions and users across China. Its AI-driven smart health management solutions, such as “Ruixinbao” and “Ruifeibao,” have become new favorites among institutions. The acquisition of the Class III Medical Device Registration Certificate from the National Medical Products Administration (NMPA) for its lung cancer diagnosis product enables “Ruifeibao” to offer a more professional, intelligent, and precise health management model in the health checkup sector.

Meanwhile, DeepWise has partnered with primary healthcare institutions to establish regional cloud imaging centers serving medical consortia. By extending AI capabilities to township health centers through telemedicine, it empowers grassroots medical institutions under initiatives such as the “Thousand Counties Project,” enabling more people to benefit from standardized, intelligent healthcare services.

In the era of large models, DeepWise’s SAMI, a general-purpose large model for medical image segmentation, is compatible with multimodal medical data. It achieves sub-second segmentation at various levels—from organs and lesions to pathological cells, diseased tissues, and cellular components—providing an AI one-click solution for all image segmentation tasks in medical practice.

DeepWise’s robust independent R&D capabilities and scientific research strength are widely recognized within the industry. Its collaborative research achievements with multiple domestic institutions have been honored with numerous awards, including the National Science and Technology Progress Award and provincial-level Science and Technology Progress Awards.

It is undeniable that although the application of AI products in the medical field has become commonplace, the industry still lacks effective monetization models on the enterprise side. Consequently, achieving large-scale commercial implementation remains a challenge that all AI companies must confront.

In addressing the challenge of commercialization, DeepWise has achieved remarkable success through its numerous initiatives in recent years. Its core team—comprising sales and marketing professionals, product R&D specialists, and researchers from the DeepWise Research Institute—consists of industry elites from diverse fields and backgrounds. Together, they have built strong market competitiveness. With unwavering resilience, the company has actively expanded application scenarios, developing a mature and highly effective multi-scenario, multi-pronged sales model. This approach has yielded significant results, evidenced by a steadily rising market share in recent years, stable cash flow, and overall performance that far outpaces competitors, creating an industry miracle.

In November 2024, the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration jointly formulated the “Reference Guidelines for AI Application Scenarios in the Health Sector.” Covering four major domains—“AI + Healthcare Service Management,” “AI + Primary Public Health Services,” “AI + Health Industry Development,” and “AI + Medical Education and Research”—the guidelines outline 84 application scenarios. This initiative aims to promote innovative development of “AI+” applications in the health sector and chart the course for the future development of medical artificial intelligence.

Looking back at the development of DeepWise, we are surprised to find that every step of its product planning seems to align perfectly with the guidance of real-world clinical scenarios. Perhaps this apparent coincidence is precisely the secret to DeepWise’s success, making it difficult for others to replicate. It is hard enough to do one thing right; doing it right early on is even harder.

Taking DeepWise’s flagship product, Deepwise MetAI, as an example, we can see that its product planning strategy is distinctive. Disease diagnosis is a complex workflow, far more than just the detection of a single sign. Currently, most AI imaging products offer point-specific diagnostic capabilities. While they can improve physicians’ efficiency in certain steps to some extent, their impact on the overall workflow remains limited. If we liken the disease diagnosis process to a cross-country run, existing AI imaging products may help physicians speed up on certain stretches but become ineffective at the next stage. The support provided by AI to physicians is intermittent, which may be one of the key obstacles preventing large-scale commercial adoption of AI, as it fails to provide continuous support throughout the entire clinical workflow.

DeepWise Medical’s Deepwise MetAI adopts an “AI-integrated full-process” approach, highly integrating various physician needs and applications—such as intelligent medical image reconstruction, computer-aided diagnosis, automated generation of structured reports, and multimodal data research—to truly achieve AI-driven digital intelligence across the entire workflow and all scenarios. Equipped with high-performance computing power and robust concurrent processing capabilities, it intelligently manages departmental GPUs, dynamically allocates computational resources in real time, and establishes a “dual-bus” architecture for medical imaging and data deconstruction. This enables physicians to freely access data and holistically optimize workflows across every stage: screening, diagnosis, treatment, management, education, and research. Rather than providing fragmented support at isolated steps, Deepwise MetAI delivers comprehensive, end-to-end assistance throughout the entire clinical journey. It also offers full-cycle AI support for the aggregation, governance, research, and application of clinical multimodal data. DeepWise Medical’s AI products are becoming the high-tech running shoes for physicians on their arduous long-distance run—providing unwavering support and accompanying them every step of the way.

Over the past eight years, DeepWise has been committed to pursuing a development path that brings medical AI capabilities infinitely closer to those of real physicians. We believe it will gradually enrich the ecosystem, achieving the leap from “useful” to “essential,” and making AI a true end-to-end assistant for doctors.

In the Year of the Snake, the sudden emergence of DeepSeek has sparked intense public discussion and deep reflection on the future trajectory of artificial intelligence. A new era of AI is dawning. From everyday users to industry experts, and from tech media to investment firms, all eyes are on AI. Whether in terms of specialized talent, investment capital, the number of startups, or other dimensions, AI will continue to drive a revolution that is ever-expanding in both depth and breadth. The impact on the overall development of the industry is immeasurable for both institutions and enterprises. We are bound to witness the emergence of more new demands, the exploration of more new applications, the proliferation of highly efficient solutions, and an increasing number of high-quality companies embracing this hundred-billion-dollar emerging market together.

Today, with its leading technology, comprehensive product portfolio, and robust cash flow, DeepWise clearly has more strategic options. Amid the emerging trends, this leading enterprise in the digital intelligence healthcare sector is once again accelerating, poised to spearhead a new transformation in medical AI.